**Antibiotics, Antidepressants Play Role in IBS Update**

**BY DAMIAN McNAMARA**

Miami Bureau

**ORLANDO —** A recommendation for antibiotic therapy to combat bacterial overgrowth, a stronger recommendation for antidepressants to ease symptoms, and serum testing for celiac disease are forthcoming updates to the American College of Gastroenterology's irritable bowel syndrome guidelines.

New recommendations on the diagnosis of irritable bowel syndrome (IBS) are also expected in the updated guidelines, which the college plans to publish in January 2009, with an earlier release online.

The guidelines also will recommend the addition of microscopic colitis to the differential diagnosis of IBS. This addition is based on the findings from a prospective, multicenter study that 4% of 454 people suspected of IBS actually had microscopic colitis.

“This is definitely new ... and potentially a very, very important message from this document,” Dr. William D. Chey said during a media briefing at the annual meeting of the American College of Gastroenterology.

“If a patient has diarrhea-predominant IBS and undergoes colonoscopy, then it is reasonable to consider taking random biopsies to exclude microscopic colitis,” said Dr. Chey, professor of medicine at the University of Michigan, Ann Arbor.

The updated diagnosis recommendations will be reassuring for many health care providers Dr. Chey continued. “Doctors are uncomfortable with assigning a diagnosis of IBS. They are worried that they are missing something else” such as colon cancer, ulcerative colitis, or Crohn’s disease.

“The reassuring bit of information that comes out of our analysis is that the likelihood of a person who has IBS symptoms plus other warning signs such as unexplained weight loss, GI bleeding, or a family history of colon cancer, inflammatory bowel disease, or thyroid disease is no greater than in the general population,” he continued. “Although

Dr. Chey said that physicians may be concerned about increasing antibiotic use, he added. However, “These recommendations, based on the best available evidence, apply to people with pain and altered bowel habits. The link between pain and bowel disturbance is very close, Dr. Nicholas J. Talley said.

“They have pain, they pass stool and get relief—that is IBS. It’s absolutely obvious to me.” Dr. Talley is chair of the department of internal medicine at the Mayo Clinic, Jacksonville, Fl.

Because of a greater risk of organic disease, patients who present with IBS symptoms plus other warning signs such as unexplained weight loss, GI bleeding, or a family history of colon cancer, inflammatory bowel disease, or celiac sprue require a more detailed evaluation, Dr. Chey said.

Another new recommendation is for use of a “nonabsorbable antibiotic” to relieve IBS symptoms.

The only approved antibiotic that remains in the gut to alter flora without systemic absorption is rifaximin (Xifaxan), now under investigation as a treatment for IBS. Rifaximin was found to be superior to placebo for improvement of IBS symptoms, especially bloating, in recent studies (Ann. Pharmacother. 2008;42:408-12; Adv. Med. Sci. 2007;52:139-42).

“What is uncertain is how long the symptom relief lasts and what you should do if the symptoms recur,” said Dr. Philip S. Schoenfeld, a gastroenterologist at the University of Michigan, who also spoke at the media briefing.

“What is uncertain is how long the symptom relief lasts and what you should do if the symptoms recur.”

**DR. SCHOENFELD**
resistance if the agents are given to thousands of IBS patients.

In addition, there is a greater focus on the use of antidepressants to treat IBS in the new guidelines.

For example, “there is a stronger recommendation that tricyclic antidepressants, used in low doses before people go to sleep at night, are an effective medicine for irritable bowel syndrome,” Dr. Schoenfeld said.

The agents can reduce bloating and discomfort by altering brain-gut signaling about motility and distention. He added that constipation, a side effect of tricyclic antidepressants, is actually beneficial in this population.

The likelihood of a person who has IBS symptoms and no warning signs having some other organic diagnosis is no greater than in the general population.

The authors of the guidelines also found enough evidence to support SSRIs for symptom improvement. “I want to emphasize that this does not appear to be related to depression,” Dr. Talley said. “This appears to be related to effects of these drugs either in the brain or the gut, but probably both places.”

Some treatment recommendations in the guidelines are not expected to change, including the use of loperamide (Imodium) or alosetron (Lotronex).

The new recommendation for serologic celiac disease testing is for a subset of IBS patients.

“We made a much stronger recommendation for testing for celiac disease in patients with diarrhea-predominant or mixed IBS,” Dr. Chey said. “We actually came out and said serologic screening for celiac disease should be pursued.”

Evidence of benefit from probiotics is also addressed. “Every one of my patients with IBS asked about probiotics,” Dr. Talley said.

“The guidelines will basically say that probiotics are efficacious, but the evidence supporting this is not as good as we would like,” he stated. The large number of probiotic products with varying degrees of efficacy precluded a stronger recommendation.

“Probiotics seem to be relatively safe as well, based on the data we have,” Dr. Talley said. “So I’m not uncomfortable with recommending a probiotic to my patients.”

He added, however, that some people are nonresponders.

In addition, recent evidence that indicates peppermint oil improves IBS symptoms will be in the update.

Dr. Schoenfeld disclosed that he is a consultant to, and is on the advisory committee for, Salix Pharmaceuticals Ltd., which markets Xifaxan.

Dr. Talley is also a consultant for Salix and a variety of other pharmaceutical companies, and receives financial support from several firms.

Dr. Chey reported no relevant financial disclosures for his presentation.

SIZING UP THE HEART-HEALTHY FACTS

The case for 23 almonds a day.

WE'RE THE SNACK THAT LOVES HEARTS BACK

It may be news to some, but we’ve known for a long time what a huge difference a handful of California Almonds can make. From being good for your heart to staying off hunger to getting a nutrient-rich boost, eating 23 almonds every day (an ounce to be exact) is a heart-healthy habit everyone should develop.

WE SUPPORT GOOD CHOLESTEROL HEALTH

Nine clinical studies over the last thirteen years have shown that almonds can lower cholesterol as part of a diet low in saturated fat. These groundbreaking studies show how a handful of almonds a day consistently lowered LDL cholesterol levels. And because people love eating them, almonds are an ideal way for cholesterol-conscious patients to maintain healthy numbers. If you’ve got time, these clinical studies make fascinating reading. In fact, when the FDA read the research, it influenced their first Qualified Health Claim for nuts:

“Scientific evidence suggests but does not prove that eating 1.5 ounces per day of most nuts, such as almonds, as part of a diet low in saturated fat and cholesterol may reduce the risk of heart disease.”

OUR GOOD FATS RUN DEEP

Good things happen when you get good fats. Almonds with 9 grams of monounsaturated fat per serving, we’re full of it. In fact, over 60 percent of the fat in almonds is monounsaturated, making us the leading source among America’s most-consumed nuts.

NUTRIENT RICH & EXTRA CRUNCHY: A TEMPTING COMBINATION

Ounce for ounce almonds are one of the most nutrient-rich nuts around. We’d list them all if we had more room. But if you’re looking for a tasty snack that’s an excellent source of three dietary nutrients, a good source of three, and has 5 grams of fiber and 6 grams of protein per serving—while packing a heck of a crunch—then we’re your nut.

MAKE THE CASE TO YOUR PATIENTS

Once you’ve sized up the facts, we hope you’ll recommend your patients develop a 23-almond-a-day snack habit. Send your patients to our website to learn more and get a designer almond carrying case they can take their daily dose wherever they go.